Follow
John P. Seibyl
John P. Seibyl
Institute for Neurodegenerative Disorders
Verified email at indd.org
Title
Cited by
Cited by
Year
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses
JH Krystal, LP Karper, JP Seibyl, GK Freeman, R Delaney, JD Bremner, ...
Archives of general psychiatry 51 (3), 199-214, 1994
41581994
MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder
JD Bremner, P Randall, TM Scott, RA Bronen, JP Seibyl, SM Southwick, ...
The American journal of psychiatry 152 (7), 973, 1995
24411995
Levodopa and the progression of Parkinson's disease
Parkinson Study Group
New England Journal of Medicine 351 (24), 2498-2508, 2004
23522004
The Parkinson progression marker initiative (PPMI)
K Marek, D Jennings, S Lasch, A Siderowf, C Tanner, T Simuni, C Coffey, ...
Progress in neurobiology 95 (4), 629-635, 2011
16602011
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.
M Laruelle, A Abi-Dargham, CH Van Dyck, R Gil, CD D'Souza, J Erdos, ...
Proceedings of the National Academy of Sciences 93 (17), 9235-9240, 1996
16541996
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort
A Abi-Dargham, R Gil, J Krystal, RM Baldwin, JP Seibyl, M Bowers, ...
American journal of psychiatry 155 (6), 761-767, 1998
11391998
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
RG Holloway, I Shoulson, S Fahn, K Kieburtz, A Lang, K Marek, ...
Archives of neurology 61 (7), 1044-1053, 2004
7002004
Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl) tropane and single photon emission computed tomography
RT Malison, LH Price, R Berman, CH van Dyck, GH Pelton, L Carpenter, ...
Biological psychiatry 44 (11), 1090-1098, 1998
6431998
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
O Hansson, J Seibyl, E Stomrud, H Zetterberg, JQ Trojanowski, T Bittner, ...
Alzheimer's & dementia 14 (11), 1470-1481, 2018
6382018
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study
H Barthel, HJ Gertz, S Dresel, O Peters, P Bartenstein, K Buerger, ...
The Lancet Neurology 10 (5), 424-435, 2011
6332011
Clinical significance of neurological soft signs in schizophrenia: factor analysis of the Neurological Evaluation Scale
RA Sewell, EB Perry Jr, LP Karper, MD Bell, P Lysaker, JL Goulet, ...
Schizophrenia research 124 (1-3), 1-12, 2010
5872010
Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease
JP Seibyl, KL Marchek, D Quinlan, K Sheff, S Zoghbi, Y Zea‐Ponce, ...
Annals of Neurology: Official Journal of the American Neurological …, 1995
5731995
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study
O Sabri, MN Sabbagh, J Seibyl, H Barthel, H Akatsu, Y Ouchi, K Senda, ...
Alzheimer's & dementia 11 (8), 964-974, 2015
5332015
Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.
RB Innis, JP Seibyl, BE Scanley, M Laruelle, A Abi-Dargham, E Wallace, ...
Proceedings of the National Academy of Sciences 90 (24), 11965-11969, 1993
4821993
[sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease
KL Marek, JP Seibyl, SS Zoghbi, Y Zea-Ponce, RM Baldwin, B Fussell, ...
Neurology 46 (1), 231-237, 1996
4611996
The Parkinson's progression markers initiative (PPMI)–establishing a PD biomarker cohort
K Marek, S Chowdhury, A Siderowf, S Lasch, CS Coffey, ...
Annals of clinical and translational neurology 5 (12), 1460-1477, 2018
4522018
Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson …
JH Kang, DJ Irwin, AS Chen-Plotkin, A Siderowf, C Caspell, CS Coffey, ...
JAMA neurology 70 (10), 2013
4462013
[123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression
K Marek, R Innis, C Van Dyck, B Fussell, M Early, S Eberly, D Oakes, ...
Neurology 57 (11), 2089-2094, 2001
4272001
Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects
AD Joshi, MJ Pontecorvo, CM Clark, AP Carpenter, DL Jennings, ...
Journal of Nuclear Medicine 53 (3), 378-384, 2012
3982012
The role of radiotracer imaging in Parkinson disease
B Ravina, D Eidelberg, JE Ahlskog, RL Albin, DJ Brooks, M Carbon, ...
Neurology 64 (2), 208-215, 2005
3852005
The system can't perform the operation now. Try again later.
Articles 1–20